TrialBMC cancer2023

Evaluation of the interest to combine a CD4 Th1-inducer cancer vaccine derived from telomerase and atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma: a randomized non-comparative phase II study (TERTIO - PRODIGE 82).

Angélique Vienot et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.